Unlocking value early in drug development and increasing the translational power of preclinical studies.
The use of biomarkers has the potential to increase value early in drug development by extracting more data and information from each study. This can increase efficiency, reduce costs, guide decisions, boost the translational power of preclinical studies, and effectively enable more drug candidates to move forward.
MD Biosciences has expertise with biomarker analysis for markers that play a role in neuroinflammation, neurodegeneration, and pain. Examples of methods we incorporate are listed below.
Whitepaper: Translational Biomarkers
This whitepaper provides an overview of how biomarkers can be utilized to extract maximum value early in translational studies while being optimized for use in clinical studies.
Whitepaper: Inflammatory Biomarkers
The interplay between the central and peripheral nervous systems and the immune response highlights the importance of understanding the cellular and inflammatory attributes that are strongly associated with neurological diseases and pain.
Whitepaper: High Precision Biomarker Detection
Multiplex and ultra-sensitive detection assays provide a powerful platform for difficult to measure analytes. The detection of these markers offers invaluable insight on monitoring disease progression at earlier stages and assessing the need for therapeutic intervention.
Ready to discuss your project?
If you are ready to discuss how electrophysiology can add to your understanding of your therapeutic potential, our scientists are eager to explore the possibilities with you. Like many other pharmaceutical and medical device developers, you can rely on predictive preclinical data.